Improving Treatment for Advanced Prostate Cancer
Mené sur 1 125 hommes atteints d’un cancer de la prostate métastatique et résistant à la castration (durée médiane de suivi : 34 mois), cet essai randomisé de phase III évalue l’efficacité, du point de vue de la survie globale, et la toxicité de l'ajout de l'enzalutamide à un traitement anti-androgénique en combinaison ou non avec le docétaxel en traitement précoce
For about 75 years, the primary treatment for men with metastatic prostate cancer has been with androgen-deprivation therapy, by either surgical or medical castration. About 90% of men respond to such therapy with an improvement in symptoms and a reduction in serum levels of prostate-specific antigen (PSA), with a median response duration of approximately 18 months. Subsequent treatments with first-generation inhibitors of the androgen receptor, such as flutamide and bicalutamide, and chemotherapy with docetaxel or other drugs can provide short-term palliation for some men. The median duration of survival with these treatments is approximately 2.5 years. Additional research has shown . . .